Description
CRLX101 is under investigation for the treatment of colorectal cancer. It has shown promise in preclinical studies but its efficacy and safety profile are still being evaluated in clinical trials; it has not yet been approved by regulatory agencies like the FDA.
Mechanism of Action
CRLX101 is an investigational nanoparticle drug that encapsulates the topoisomerase I inhibitor irinotecan, designed to improve its pharmacokinetics and reduce toxicity.
Side Effects
Neutropenia; diarrea; fatiga; náuseas; vómito
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT02010567
Phase 1
Archived
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
United States
Quick Info
| Category | Other Medications |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.